LifeMD, Inc. (NASDAQ:LFMD – Get Rating) – Equity research analysts B. Riley have cut their fiscal year 2023 earnings estimates for LifeMD shares in a research report released to clients and investors. investors on Thursday, February 24. B. Riley analyst M. Wiesenberger now expects the company to post earnings per share of $0.16 for the year, down from its previous forecast of $0.27.
Several other brokerage firms also weighed in on LFMD. Zacks Investment Research downgraded LifeMD from a “buy” rating to a “hold” rating in a Tuesday, January 25 report. BTIG Research lowered its price target on LifeMD from $30.00 to $15.00 and set a “buy” rating for the company in a Thursday, November 11 report.
LifeMD stock opened at $3.55 on Monday. LifeMD has a 52-week minimum of $2.72 and a 52-week maximum of $23.45. The company’s 50-day moving average price is $3.72. The company has a market capitalization of $108.61 million, a P/E ratio of -0.84 and a beta of 0.71.
In the same vein, director Bertrand Velge bought 25,000 shares in a transaction dated Tuesday, December 7. The stock was purchased at an average cost of $4.54 per share, with a total value of $113,500.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Additionally, Director Naveen Bhatia acquired 50,000 LifeMD shares in a trade dated Tuesday, November 30. The shares were acquired at an average price of $3.88 per share, with a total value of $194,000.00. Disclosure of this purchase can be found here. Insiders have purchased 192,831 shares of the company valued at $769,629 over the past ninety days. Company insiders hold 35.56% of the company’s stock.
A number of institutional investors and hedge funds have recently increased or reduced their stake in LFMD. Newbridge Financial Services Group Inc. acquired a new stake in LifeMD in the third quarter worth approximately $25,000. CWM LLC acquired a new stake in LifeMD in the fourth quarter worth approximately $39,000. Virtu Financial LLC acquired a new stake in shares of LifeMD during the 4th quarter at a value of $47,000. Cambridge Investment Research Advisors Inc. acquired a new equity stake in LifeMD during the 4th quarter valued at $54,000. Finally, Marshall Wace LLP acquired a new equity stake in LifeMD during Q3 for $70,000. Hedge funds and other institutional investors hold 27.48% of the company’s shares.
About LifeMD (Get a rating)
LifeMD, Inc. is a telehealth company, committed to offering a portfolio of direct-to-patient products and services. It combines virtual medical treatment with prescription drugs and over-the-counter products. The company’s network of licensed physicians provides telemedicine services and direct pharmacy to consumers across the United States.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in LifeMD right now?
Before you consider LifeMD, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market ripples…and LifeMD wasn’t on the list.
Although LifeMD currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here